ReviewDrug-induced Osteoporosis: Mechanisms and Clinical Implications
Section snippets
Glucocorticoids
Glucocorticoids are used in the treatment of inflammatory and autoimmune diseases, neoplasias, and following organ transplantation. Glucocorticoid-induced osteoporosis is the most common form of secondary osteoporosis. The central mechanism of action of glucocorticoids is decreased bone formation, secondary to impaired osteoblastic differentiation and function.1 However, during the initial phases of glucocorticoid exposure, bone resorption is increased, explaining an early bone loss.2
Psychotropic and Anticonvulsant Therapy
Selected drugs with central nervous system effects may alter skeletal metabolism. This has clinical relevance because patients taking these drugs are often elderly and frail, with a propensity to fall and, consequently, to fracture.
Heparin
Heparin is effective in the prevention and treatment of venous thromboembolism. In vitro, heparin inhibits the differentiation and function of osteoblasts.51 In vivo, heparin decreases bone formation and increases bone resorption, the latter by inhibiting the expression of osteoprotegerin, a decoy receptor for receptor activator of nuclear factor–kappa B ligand.51
In pregnant women, up to one third of patients placed on heparin have a significant decrease in BMD, with fractures occurring in only
Calcineurin Inhibitors
Calcineurin inhibitors are immunosuppressants used in combination with glucocorticoids in patients undergoing organ transplantation. In vitro, cyclosporine and tacrolimus inhibit osteoclastogenesis and bone resorption.63 However, in vivo, these drugs cause bone loss due to markedly increased bone resorption.64 Changes in T-cell cytokine production and altered vitamin D metabolism with secondary hyperparathyroidism may contribute to the effects of calcineurin inhibitors. Furthermore, it is not
Proton Pump Inhibitors
Proton pump inhibitors are commonly used in the treatment of diseases of the upper gastrointestinal tract. In vitro, the inhibition of proton pumps on the osteoclast ruffled border may decrease bone resorption.72 However, proton pump inhibitors decrease intestinal calcium absorption, increasing bone resorption in vivo. Proton pump inhibitors decrease BMD at the lumbar spine and hip, and increase the risk of vertebral and nonvertebral fragility fractures, depending on drug dose and duration of
Conclusions
Drugs routinely used for treatment of multiple diseases have detrimental effects on the skeleton. Awareness of this clinical problem is limited, and consequently, preventive measures are often not undertaken. Adequate monitoring of bone health and therapeutic intervention are recommended when drugs with an adverse bone safety profile are used, particularly in patients with additional risk factors for osteoporosis.
Acknowledgment
The authors thank Mary Yurczak for secretarial assistance.
References (75)
- et al.
High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study
Bone
(2006) - et al.
Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density
Bone
(2010) - et al.
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
Ann Oncol
(2009) - et al.
Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozolePrevention with bisphosphonates
Bone
(2007) - et al.
Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study
Lancet Oncol
(2007) - et al.
The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish women
Contraception
(2008) - et al.
Incidence and risk factors for low trauma fractures in men with prostate cancer
Bone
(2008) - et al.
Vertebral fractures in males with type 2 diabetes treated with rosiglitazone
Bone
(2009) - et al.
Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum
Cell
(2008) - et al.
The effects of heparin and low molecular weight heparins on bone
Thromb Res
(2008)
Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin
Am J Obstet Gynecol
Effects of warfarin on boneStudies on the vitamin K-dependent protein of rat bone
J Biol Chem
Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study
Lancet
Glucocorticoid-induced osteoporosis: pathophysiology and therapy
Osteoporos Int
Use of oral corticosteroids and risk of fractures
J Bone Miner Res
Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures
Calcif Tissue Int
Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy
Arthritis Rheum
US and UK guidelines for glucocorticoid-induced osteoporosis: similarities and differences
Curr Rheumatol Rep
Prevention and treatment of glucocorticoid-induced osteoporosis
J Endocrinol Invest
The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression
J Bone Miner Res
Teriparatide or alendronate in glucocorticoid-induced osteoporosis
N Engl J Med
Thyroxine prescription in the community: serum thyroid stimulating hormone level assays as an indicator of undertreatment or overtreatment
Br J Gen Pract
The clinical significance of subclinical thyroid dysfunction
Endocr Rev
Thyroid hormones: beneficial or deleterious for bone?
Calcif Tissue Int
Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma
J Bone Miner Res
Levothyroxine treatment and occurrence of fracture of the hip
Arch Intern Med
Risk for fracture in women with low serum levels of thyroid-stimulating hormone
Ann Intern Med
Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate
Thyroid
Cancer treatment-related bone loss: a review and synthesis of the literature
Curr Oncol
Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole
Oncologist
Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial
J Clin Oncol
Endocrine therapy plus zoledronic acid in premenopausal breast cancer
N Engl J Med
Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer
J Clin Oncol
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer
J Clin Oncol
Bone densitometry as an adjunct to GnRH agonist therapy
J Reprod Med
Recovery of bone density in women who stop using medroxyprogesterone acetate
BMJ
Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer
J Clin Endocrinol Metab
Cited by (217)
Effects of Medical Treatment of Prostate Cancer on Bone Health
2021, Trends in Endocrinology and MetabolismDenosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors
2024, Journal of Endocrinological InvestigationCholecalciferol Use Is Associated With a Decreased Risk of Incident Morphometric Vertebral Fractures in Acromegaly
2024, Journal of Clinical Endocrinology and Metabolism
Funding: This work was supported by MIUR and Centro di Ricerca sull'Osteoporosi-University of Brescia/EULO (A. Giustina).
Conflict of Interest: Dr. Mazziotti has nothing to declare. Dr. Canalis reports receiving consulting or lecture fees from Eli Lilly, GlaxoSmithKline, Novartis, and Amgen. Dr. Giustina reports receiving consulting or lecture fees from Abiogen, Eli Lilly, GlaxoSmithKline, Merck, Amgen, and Stroder. No pharmaceutical industry funds were received for the preparation of the manuscript or related research.
Authorship: Each author has participated in the writing of the manuscript and has seen and approved the submitted version. Further, each author has been involved in the conception and design of the study and the analysis of the data.